Sector News

Booming WuXi eyes $1.5B IPO for biologics unit: report

February 26, 2016
Life sciences

Just months after taking the company private in a $3.3 billion deal, WuXi CEO Ge Li has begun setting the stage to spin out its rocketing biologics unit in an IPO that would value the business at $1.5 billion, according to a report from Bloomberg.

Based in Shanghai with facilities in the U.S., WuXi has achieved remarkably fast growth, emerging as the biggest contract research organization in China with extensive R&D and manufacturing ties throughout the world. In just the last few months the company has:

  • Blueprinted a $120 million, 250,000-square-foot biologics discovery hub in Shanghai, with plans to bring together some 800 scientists.
  • Struck a deal to jointly produce biologics with AstraZeneca, which has partnered with WuXi on the development and commercialization of MEDI5117. AstraZeneca also has an option to buy a manufacturing facility from WuXi for $100 million.
  • Added $290 million to its venture fund as it takes a stake in a growing group of U.S. biotechs that now includes Juno, Agios and Twist Biosciences.

Bank of America and Morgan Stanley have been brought in to handle a Hong Kong share sale, Bloomberg reports, citing sources close to the deal. WuXi pulled out of the New York Stock Exchange on December 10.

Ge Li and his top executive crew have earned a reputation for fast-paced dealmaking that’s unprecedented in China’s growing biopharma business. And clearly they’re still in the early stages of wheeling and dealing with some of the biggest, and smallest, players in the global industry.

By John Carroll

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.